Concerns about pregabalin: Further experience with its potential of causing addictive behaviors

Journal of Addiction Medicine

Volumn 7, Issue 2, 2013, Pages 147-149

  Gahr, Maximilian ^a   Franke, Beate ^a   Freudenmann, Roland W ^a   Kölle, Markus A ^a   Schönfeldt Lecuona, Carlos ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Abuse; Addiction; Antiepileptic drug; Dependence; Pharmacovigilance

Indexed keywords

AGOMELATINE; ALCOHOL; AMISULPRIDE; PREGABALIN; VENLAFAXINE;

ADULT; ALCOHOL ABUSE; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; BORDERLINE STATE; CASE REPORT; CONSULTATION; DETOXIFICATION; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DSM-IV; EUPHORIA; FEMALE; HUMAN; MAJOR DEPRESSION; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADULT; ALCOHOLISM; ANALGESICS; ANXIETY DISORDERS; BEHAVIOR, ADDICTIVE; BORDERLINE PERSONALITY DISORDER; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84877942112     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3182872718     Document Type: Article

References (26)

1. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49: 661-669.
2. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol 2012;32: 839-840.
3. Caster O, Edwards I, Norén G, et al. Earlier discovery of pregabalin's dependence potential might have been possible. Eur J Clin Pharmacol 2011;67: 319-320.
4. Chalabianloo F, Schjøtt J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen 2009;129: 186-187.
5. Chesler E, Ritchie J, Kokayeff A, et al. Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 2003;106: 325-335.
6. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Fed Regist 2005;70: 43633-43635.
7. Filipetto F, Zipp C, Coren J. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 2010;110: 605-607.
8. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010;167: 869.
9. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positiveinternal- controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 2005;183: 133-143.
10. Kruszewski SP, Paczynski RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract 2009;15: 314-319.
11. Landmark C, Fossmark H, Larsson P, et al.. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen 2011;131: 223.
12. Lanneau C, Green A, Hirst W, et al. Gabapentin is not a GABAB receptor agonist. Neuropsychopharmacology 2001;41: 965-975.
13. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010;196: 4-12.
14. Lyrica (pregabalin) capsules [prescribing information]. New York, NY: Pfizer, Inc, Revised June 2011.
15. Martin D, McClelland D, Herd M, et al. Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropsychopharmacology 2002;42: 353-366.
16. McAuley D. How does pregabalin compare to gabapentin in the treatment of neuropathic pain? Available at: http://www. globalrph. com/pregabalin. htm. Published 2005. Accessed August 30, 2012.
17. No authors listed. Gabapentin and pregabalin: abuse and addiction. Prescrire Int 2012;21: 152-154.
18. Pittenger C, Desan P. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J Clin Psychiatry 2007;68: 483-484.
19. Rose M, Kam P. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57: 451-462.
20. Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010;74: 755-761.
21. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80: 118-122.
22. Schwan S, Sundström A, Stjernberg E, et al E. Asignal for an abuse liability for pregabalin - results from the Swedish spontaneous drug reaction reporting system. Eur J Clin Psychopharmacol 2010;66: 947-953.
23. Sills G. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006;6: 108-113.
24. Skopp G, Zimmer G. Pregabalin - a drug with abuse potential? Arch Kriminol 2012;229: 44-54.
25. Vicctorio-Vigneau C, Guerlais M, Jolliet M. Abuse, dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry 2007;40: 43-44.
26. Zacny J, Paice J, Coalson D. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 2012;100: 560-565.